Upon the outbreak of the COVID-19 pandemic, many research labs refocused their attentions to work on the novel virus. Those working with the gene-editing tool CRISPR were no exception and the technique has since been utilized to develop fast, diagnostic tests for the disease, as well as a potential new treatment. Over the past year, CRISPR has gained its first Emergency Use Approval from the US FDA and many are looking to the technique to solve the issue of dwindling testing capacity. However, the technique still has its challenges to overcome and it will likely take time before a COVID-19...
To view this content, please register now for access
Become a member of BioTechniques for FREE to receive:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!